Novasenta is focused on the discovery of novel therapeutic targets to develop innovative and effective treatments for cancer patients. The company has developed a proprietary platform for single-cell RNA based analysis of high-quality, human tumor samples and combined it with its advanced data mining and target validation abilities to accelerate the path from discovery to drug development. The company’s pipeline includes three programs representing the next generation of immuno-oncology targets and drug candidates.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):